Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.

X

Navigate / search

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)

Key Dates: 
  • Posted Date: December 11, 2014
  • Open Date (Earliest Submission Date): January 16, 2015
  • Letter of Intent Due Date(s): Not Applicable
  • Application Due Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • AIDS Application Due Date(s): Standard AIDS dates apply by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • Scientific Merit Review: Standard dates apply
  • Advisory Council Review: Standard dates apply
  • Earliest Start Date: Standard dates apply
Purpose: 

This FOA provides funding to conduct pharmacodynamics, pharmacokinetics, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for NINDS Cooperative Research to Enable and Advance Translational Enterprises program (CREATE) for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational program.

Expiration Date: 
Monday, January 8, 2018
Announcement Number: 
PAR-15-071